Metastases
Conditions
Keywords
Benefit of, adjuvant, treatment, prostatectomy
Brief summary
PRINCIPAL OBJECTIVE: Evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence. SECONDARY OBJECTIVE(S): * PSA evolution * Evaluation of testosterone level * Specific survival * Overall survival * Tolerance * Quality of life (QLQ-C30 questionnaires)
Interventions
DRUGLeuprorelin Acetate
Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
Sponsors
Astellas Pharma Inc
UNICANCER
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients who have received the information leaflet and signed the consent form 2. ≥18 years of age with a life expectancy of at least 10 years 3. Performance Status (ECOG) ≤2 4. Radical prostatectomy (RP) with or without extended pelvic lymphadenectomy in the 3 months preceding inclusion 5. Histologically confirmed prostatic adenocarcinoma 6. Patients R0, N0 or Nx or N+ (≤ 2 nodes among nodes removed), M0 and with at least one of the following criteria: * postoperative Gleason score \>7 * postoperative Gleason score =7 with the presence of high-grade Gleason patterns * pT3b patients 7. Postoperative PSA \<0.1 ng/mL (dosage perform within 2 months after surgery) 8. Neutrophils ≥1500/mm³, platelets ≥100000/mm³ 9. Bilirubin ≤ upper normal limit (this will not apply to subjects with Gilbert's syndrome, persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of hemolysis or hepatic pathology); ASAT and ALAT ≤1.5 times upper normal limit; Creatinine \<140 µmol/l (or clearance \>60 mL/min) 10. Patients affiliated to a social security scheme
Exclusion criteria
1. Previous treatments for prostatic adenocarcinoma (HT or orchiectomy or CT) 2. Presence of metastases: * positive bone scintigraphy, including Patients with medullary compression and/or * abdominal-pelvic CT scan or MRI showing lymph node and/or visceral involvement 3. History of cancer, with the exception of basal cell carcinoma or any other cancer treated in the 5 years before inclusion and in complete remission 4. Incompatible concomitant treatment(s) 5. Hypersensitivity to other GnRH agonists and/or any of the excipients of Eligard® 6. Any illness or problem including geographic, psychiatric or psychological which is incompatible with being monitored during the trial 7. Persons deprived of their freedom or under supervision (including guardianship), 8. Patients already included in another therapeutic trial with an experimental drug or having been given an experimental drug within a period of 30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The principal criterion is the evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy. | The principal criterion will be evaluated 12 years after the inclusion of the first patient. |
Countries
France
Outcome results
None listed